Skip to main content
Erschienen in: International Journal of Colorectal Disease 2/2013

01.02.2013 | Original Article

Factors predicting worse prognosis in patients affected by pT3 N0 colon cancer: long-term results of a monocentric series of 137 radically resected patients in a 5-year period

verfasst von: Roberto Biffi, Edoardo Botteri, Emilio Bertani, Maria Giulia Zampino, Sabina Cenciarelli, Fabrizio Luca, Simonetta Pozzi, Maria Laura Cossu, Antonio Chiappa, Nicole Rotmensz, Barbara Bazolli, Elena Magni, Angelica Sonzogni, Bruno Andreoni

Erschienen in: International Journal of Colorectal Disease | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

For patients with Stage II colon cancer, the use of adjuvant chemotherapy remains controversial. The purpose of this study was to identify clinical and/or pathological findings related to a worse prognosis in this category of patients.

Patients and methods

We retrospectively analyzed the data of consecutive patients, extracted by an institutional Tumour Registry, admitted to an affiliated University Hospital in Milan (European Institute of Oncology) for adenocarcinoma of the colon (all sites), between 2000 and 2005, and having a final pT3 N0 pathology staging after curative surgery. Adjuvant chemotherapy was decided as a result of a medical decision within a multidisciplinary Tumor Board.

Results

Data of 137 patients were obtained, with a median follow-up of 77 months (range 6–131). Patients who received chemotherapy were younger than patients who did not. Nine patients out of 137 (6.5 %) died as a consequence of colon cancer recurrence; four of them had received adjuvant chemotherapy. Only histological grade III and mucinous histotype were found to impact on cumulative incidence of colon-related events (p 0.03 and 0.02, respectively); no impact was found on cumulative incidence of colonic neoplasm recurrence-related deaths (p 0.74 and 0.74, respectively). Number of analyzed LNs (lymph nodes) emerged as a factor possibly affecting the cumulative incidence of colon-related events (p 0.09) as well as the cumulative incidence of colonic neoplasm recurrence-related deaths (p 0.10). The risk of events was inversely proportional to the number of dissected LNs, even over 20 up to about 25 LNs. Never-smokers exhibited a lower incidence of colon-related events, although the difference was not statistically significant (p 0.09). All other analyzed variables did not show any impact on survival rate, including age, gender, ASA score, BMI, site of colonic neoplasm, multifocality, perivascular invasion, and use of adjuvant chemotherapy.

Conclusions

Histology grading G3 and mucinous histotype were predictors of worse outcome. Efforts to improve LN evaluation should result in clinically significant improvements in outcome, and also the quality of care for patients with radically resected stage II colon cancer.
Literatur
1.
Zurück zum Zitat Greene FL, Page DL, Fleming ID et al (eds) (2002) AJCC Cancer Staging Handbook, 6th edn. Springer, New York Greene FL, Page DL, Fleming ID et al (eds) (2002) AJCC Cancer Staging Handbook, 6th edn. Springer, New York
2.
Zurück zum Zitat Greene FL, Stewart AK, Norton HJ (2002) A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 236:416–421PubMedCrossRef Greene FL, Stewart AK, Norton HJ (2002) A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 236:416–421PubMedCrossRef
3.
Zurück zum Zitat Greene FL, Stewart AK, Norton HJ (2004) New tumor-node-metastasis staging strategy for node positive (stage III) rectal cancer: an analysis. J Clin Oncol 22:1778–1784PubMedCrossRef Greene FL, Stewart AK, Norton HJ (2004) New tumor-node-metastasis staging strategy for node positive (stage III) rectal cancer: an analysis. J Clin Oncol 22:1778–1784PubMedCrossRef
4.
Zurück zum Zitat Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487PubMedCrossRef Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487PubMedCrossRef
5.
Zurück zum Zitat O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425PubMedCrossRef O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425PubMedCrossRef
6.
Zurück zum Zitat Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806PubMedCrossRef Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806PubMedCrossRef
7.
Zurück zum Zitat Benson AB III, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419PubMedCrossRef Benson AB III, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419PubMedCrossRef
8.
Zurück zum Zitat Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88:1739–1757PubMedCrossRef Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88:1739–1757PubMedCrossRef
9.
Zurück zum Zitat Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 20(375):1030–1047CrossRef Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 20(375):1030–1047CrossRef
10.
Zurück zum Zitat Botteri E, Iodice S, Maisonneuve P et al (2009) Case mix at the European Institute of Oncology: first report of the Tumour Registry, years 2000–2002. Ecancermedsci. doi:10.3332/ecancer.2009.149 Botteri E, Iodice S, Maisonneuve P et al (2009) Case mix at the European Institute of Oncology: first report of the Tumour Registry, years 2000–2002. Ecancermedsci. doi:10.​3332/​ecancer.​2009.​149
11.
Zurück zum Zitat Krasna MJ, Flancbaum L, Cody RP et al (1988) Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 61:1018–1023PubMedCrossRef Krasna MJ, Flancbaum L, Cody RP et al (1988) Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 61:1018–1023PubMedCrossRef
12.
Zurück zum Zitat Wanebo HJ, Rao B, Pinsky CM et al (1978) Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299:448–451PubMedCrossRef Wanebo HJ, Rao B, Pinsky CM et al (1978) Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299:448–451PubMedCrossRef
13.
Zurück zum Zitat Wolmark N, Fisher B, Wieand HS et al (1984) The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 199:375–382PubMedCrossRef Wolmark N, Fisher B, Wieand HS et al (1984) The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 199:375–382PubMedCrossRef
14.
Zurück zum Zitat Moertel CG, Fleming TR, Macdonald JS et al (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 13:2936–2943PubMed Moertel CG, Fleming TR, Macdonald JS et al (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 13:2936–2943PubMed
15.
Zurück zum Zitat Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551–561PubMedCrossRef Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551–561PubMedCrossRef
16.
Zurück zum Zitat Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349–1355PubMed Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349–1355PubMed
17.
Zurück zum Zitat Quasar Collaborative Group (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised trial. Lancet 370:2020–2029CrossRef Quasar Collaborative Group (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised trial. Lancet 370:2020–2029CrossRef
18.
Zurück zum Zitat Jonker DJ, Spithoff K, Maroun J, Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care (2011) Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol) 23(5):314–322CrossRef Jonker DJ, Spithoff K, Maroun J, Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care (2011) Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol) 23(5):314–322CrossRef
19.
Zurück zum Zitat Winn R, McClure J (2003) The NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 1:9 Winn R, McClure J (2003) The NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 1:9
20.
Zurück zum Zitat Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as an adjuvant treatment in stage II and III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116PubMedCrossRef Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as an adjuvant treatment in stage II and III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116PubMedCrossRef
21.
Zurück zum Zitat Goldstein NS (2002) Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol 26:179–189PubMedCrossRef Goldstein NS (2002) Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol 26:179–189PubMedCrossRef
22.
Zurück zum Zitat Sarli L, Bader G, Iusco D et al (2005) Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 41:272–279PubMedCrossRef Sarli L, Bader G, Iusco D et al (2005) Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 41:272–279PubMedCrossRef
23.
Zurück zum Zitat Swanson RS, Compton CC, Stewart AK, Bland KI (2003) The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10:65–71PubMedCrossRef Swanson RS, Compton CC, Stewart AK, Bland KI (2003) The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10:65–71PubMedCrossRef
24.
Zurück zum Zitat Baxter NN, Virnig DJ, Rothenberger DA et al (2005) Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 97:219–225PubMedCrossRef Baxter NN, Virnig DJ, Rothenberger DA et al (2005) Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 97:219–225PubMedCrossRef
25.
Zurück zum Zitat Bui L, Rempel E, Reeson D, Simunovic M (2006) Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 93:439–445PubMedCrossRef Bui L, Rempel E, Reeson D, Simunovic M (2006) Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 93:439–445PubMedCrossRef
26.
Zurück zum Zitat Jestin P, Pahlman L, Glimelius B, Gunnarsson U (2005) Cancer staging and survival in colon cancer is dependent on the quality of the pathologists’ specimen examination. Eur J Cancer 41:2071–2078PubMedCrossRef Jestin P, Pahlman L, Glimelius B, Gunnarsson U (2005) Cancer staging and survival in colon cancer is dependent on the quality of the pathologists’ specimen examination. Eur J Cancer 41:2071–2078PubMedCrossRef
27.
Zurück zum Zitat Lemmens VE, Verheij CD, Janssen-Heijnen ML et al (2006) Mixed adherence to clinical practice guidelines for colorectal cancer in the Southern Netherlands in 2002. Eur J Surg Oncol 32:168–173PubMedCrossRef Lemmens VE, Verheij CD, Janssen-Heijnen ML et al (2006) Mixed adherence to clinical practice guidelines for colorectal cancer in the Southern Netherlands in 2002. Eur J Surg Oncol 32:168–173PubMedCrossRef
28.
Zurück zum Zitat Maurel J, Launoy G, Grosclaude P et al (1998) Lymph node harvest reporting in patients with carcinoma of the large bowel: a French population-based study. Cancer 82:1482–1486PubMedCrossRef Maurel J, Launoy G, Grosclaude P et al (1998) Lymph node harvest reporting in patients with carcinoma of the large bowel: a French population-based study. Cancer 82:1482–1486PubMedCrossRef
29.
Zurück zum Zitat Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA (2007) Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 99:433–441PubMedCrossRef Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA (2007) Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 99:433–441PubMedCrossRef
30.
Zurück zum Zitat Carloss H, Huang B, Cohen A, Carloss E, Wyatt S, Tucker T (2004) The impact of number of lymph nodes removed on five-year survival in stage II colon and rectal cancer. J Ky Med Assoc 102:345–347PubMed Carloss H, Huang B, Cohen A, Carloss E, Wyatt S, Tucker T (2004) The impact of number of lymph nodes removed on five-year survival in stage II colon and rectal cancer. J Ky Med Assoc 102:345–347PubMed
31.
Zurück zum Zitat Wong JH, Bowles BJ, Bueno R, Shimizu D (2002) Impact of the number of negative nodes on disease-free survival in colorectal cancer patients. Dis Colon Rectum 45:1341–1348PubMedCrossRef Wong JH, Bowles BJ, Bueno R, Shimizu D (2002) Impact of the number of negative nodes on disease-free survival in colorectal cancer patients. Dis Colon Rectum 45:1341–1348PubMedCrossRef
32.
Zurück zum Zitat Koebrugge B, Vogelaar FJ, Lips DJ, Pruijt JF, van der Linden JC, Ernst MF, Bosscha K (2011) The number of high-risk factors is related to outcome in stage II colonic cancer patients. Eur J Surg Oncol 37(11):964–970PubMedCrossRef Koebrugge B, Vogelaar FJ, Lips DJ, Pruijt JF, van der Linden JC, Ernst MF, Bosscha K (2011) The number of high-risk factors is related to outcome in stage II colonic cancer patients. Eur J Surg Oncol 37(11):964–970PubMedCrossRef
Metadaten
Titel
Factors predicting worse prognosis in patients affected by pT3 N0 colon cancer: long-term results of a monocentric series of 137 radically resected patients in a 5-year period
verfasst von
Roberto Biffi
Edoardo Botteri
Emilio Bertani
Maria Giulia Zampino
Sabina Cenciarelli
Fabrizio Luca
Simonetta Pozzi
Maria Laura Cossu
Antonio Chiappa
Nicole Rotmensz
Barbara Bazolli
Elena Magni
Angelica Sonzogni
Bruno Andreoni
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 2/2013
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-012-1563-y

Weitere Artikel der Ausgabe 2/2013

International Journal of Colorectal Disease 2/2013 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.